spiperone has been researched along with Movement Disorders in 7 studies
Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.
spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively.
Movement Disorders: Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mishra, RK | 1 |
| Bédard, P | 1 |
| Boucher, R | 2 |
| Di Paolo, T | 2 |
| Labrie, F | 1 |
| Cross, AJ | 1 |
| Crow, TJ | 1 |
| Ferrier, IN | 1 |
| Johnson, JA | 1 |
| Johnstone, EC | 1 |
| Owen, F | 1 |
| Owens, DG | 1 |
| Poulter, M | 1 |
| Harris, JC | 1 |
| Wong, DF | 1 |
| Wagner, HN | 2 |
| Rett, A | 1 |
| Naidu, S | 1 |
| Dannals, RF | 1 |
| Links, JM | 1 |
| Batshaw, ML | 1 |
| Moser, HW | 1 |
| Crossman, AR | 1 |
| Clarke, CE | 1 |
| Boyce, S | 1 |
| Robertson, RG | 1 |
| Sambrook, MA | 1 |
| Bédard, PJ | 1 |
| Falardeau, P | 1 |
2 reviews available for spiperone and Movement Disorders
| Article | Year |
|---|---|
CNS dopamine receptors: effect of prolyl-leucyl-glycinamide and solubilization.
Topics: Adenylyl Cyclases; Animals; Binding Sites; Brain; Cattle; Dopamine; Dopamine Antagonists; Dyskinesia | 1984 |
MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Deoxyglucose; Haplorhini; Humans; Levo | 1987 |
5 other studies available for spiperone and Movement Disorders
| Article | Year |
|---|---|
Interaction between estradiol, prolactin, and striatal dopaminergic mechanisms.
Topics: Animals; Corpus Striatum; Domperidone; Dopamine; Estradiol; Female; Haloperidol; Macaca fascicularis | 1984 |
Chemical and structural changes in the brain in patients with movement disorder.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholine; Antipsychotic Agents; Brain; Choline O-Acetyltransfer | 1985 |
Positron emission tomographic study of D2 dopamine receptor binding and CSF biogenic amine metabolites in Rett syndrome.
Topics: Adult; Binding Sites; Biogenic Amines; Brain; Chromatography, High Pressure Liquid; Female; Humans; | 1986 |
Rett syndrome: positron emission tomography (PET) studies.
Topics: Adult; Age Factors; Aged; Brain; Deoxyglucose; Female; Fluorodeoxyglucose F18; Glucose; Humans; Inte | 1986 |
Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Bromocriptine; Butyrophenones; | 1986 |